Telix Pharmaceuticals Limited (TLX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -52.55M | 26.97M | 3.95M | 34.98M | 10.63M | 13.26M | -3.75M | -60.22M | -30.68M | -28.65M | 20.43M | -18.47M |
| Operating CF Margin % | -8.47% | 4.55% | 0.66% | 18.51% | 3.77% | 6% | -2.76% | -250.42% | -654.72% | -984.47% | 566.61% | -1149.47% |
| Operating CF Growth % | -1431.05% | -22.9% | -62.84% | 163.82% | 383.26% | 122.02% | 87.77% | -110.2% | -250.16% | -55.09% | 348.59% | -22.22% |
| Net Income | -7.25M | -3.48M | 20.27M | 29.37M | 19.53M | -14.32M | -33.19M | -70.89M | -48M | -32.51M | -26.59M | -18.3M |
| Depreciation & Amortization | 17.89M | 14.56M | 4.32M | 3.66M | 3.55M | 3.19M | 2.66M | 2.72M | 2.63M | 2.55M | 2.55M | 2.33M |
| Stock-Based Compensation | 0 | 17.6M | 9.72M | 9.83M | 7.47M | 1.31M | 5.84M | 2.27M | -767K | 2.09M | 787K | 1.56M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -63.19M | -1.72M | 68.47M | -7.88M | 37.6M | 23.07M | 49.58M | 5.68M | 22.87M | -769K | 44.3M | -4.07M |
| Working Capital Changes | 0 | 0 | -98.82M | 0 | -57.53M | 0 | -28.64M | 0 | -7.42M | 0 | -612K | 0 |
| Change in Receivables | 0 | 0 | -57.08M | 0 | -27.38M | 0 | -19.93M | 0 | -7.19M | 0 | -328K | 0 |
| Change in Inventory | 0 | 0 | -3.24M | 0 | -9.64M | 0 | -5.02M | 0 | -2.82M | 0 | -91K | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -41.17M | -396.34M | -89.33M | -45.62M | -22.6M | -2.89M | -5.66M | -11.34M | -1.95M | -778K | -447K | -644K |
| Capital Expenditures | -41.55M | -43.41M | -9.63M | -4.6M | -6.67M | -3.01M | -4.66M | -2.37M | -1.01M | -329K | -48K | -200K |
| CapEx % of Revenue | 6.7% | 7.32% | 1.62% | 2.43% | 2.37% | 1.36% | 3.43% | 9.87% | 21.55% | 11.31% | 1.33% | 12.45% |
| Acquisitions | 5.52M | -343.98M | -11.46M | -23.35M | -1.61M | 123K | -973K | 0 | 0 | 0 | -322K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -5.04M | -7.68M | -68.24M | -17.68M | -14.33M | 0 | -25K | -8.96M | -938K | -449K | -77K | -444K |
| Cash from Financing | -1.2M | -4.48M | 636.77M | 2.13M | 5.49M | 4.7M | 3.79M | 171.17M | 2.51M | 339K | 33.63M | 486K |
| Debt Issued (Net) | 240.65K | -690.54K | 0 | 1.5M | 0 | 1.77M | 0 | -431K | 0 | -511K | 0 | 67K |
| Equity Issued (Net) | 1.7M | 1.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -3.14M | -4.82M | 636.77M | 629.66K | 5.49M | 2.93M | 3.79M | 171.6M | 2.51M | 850K | 33.63M | 419K |
| Net Change in Cash | -97.81M | -356.11M | 591.51M | -7.07M | -8.49M | 15.4M | -6.28M | 100.57M | -27.58M | -28.33M | 53.57M | -20.22M |
| Free Cash Flow | -92.6M | 16.84M | -5.68M | 30.38M | 3.96M | 10.25M | -8.41M | -62.59M | -31.69M | -28.98M | 20.38M | -18.67M |
| FCF Margin % | -14.92% | 2.84% | -0.96% | 16.08% | 1.4% | 4.64% | -6.19% | -260.29% | -676.27% | -995.77% | 565.28% | -1161.92% |
| FCF Growth % | -1528.83% | -44.58% | -243.74% | 196.4% | 147% | 116.38% | 73.45% | -116.01% | -255.47% | -55.19% | 338.08% | -23.05% |
| FCF per Share | -0.27 | 0.05 | -0.02 | 0.09 | 0.01 | 0.03 | -0.03 | -0.20 | -0.11 | -0.10 | 0.08 | -0.07 |
| FCF Conversion (FCF/Net Income) | 7.25x | -7.74x | 0.10x | 2.99x | 0.54x | -0.93x | 0.11x | 0.85x | 0.64x | 0.88x | -0.77x | 1.01x |
| Interest Paid | 0 | 8.94M | 4.06M | 662.65K | 429K | 356K | 299K | 109K | 115K | 74K | 163K | 28K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |